H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Rubius Therapeutics (RUBY) today and set a price target of $28.00. The company’s shares closed last Monday at $4.77, close to its 52-week low of $3.35.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 4.0% and a 42.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics, Deciphera Pharmaceuticals, and Phasebio Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rubius Therapeutics with a $17.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.44 and a one-year low of $3.35. Currently, Rubius Therapeutics has an average volume of 195.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan and is headquartered in Cambridge, MA.
